GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (STU:ECX) » Definitions » 3-Year FCF Growth Rate

Epigenomics AG (STU:ECX) 3-Year FCF Growth Rate : 34.20% (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG 3-Year FCF Growth Rate?

Epigenomics AG's Free Cash Flow per Share for the three months ended in Jun. 2023 was €-3.73.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 34.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 32.00% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 20.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Epigenomics AG was 50.40% per year. The lowest was -55.90% per year. And the median was 18.25% per year.


Competitive Comparison of Epigenomics AG's 3-Year FCF Growth Rate

For the Diagnostics & Research subindustry, Epigenomics AG's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's 3-Year FCF Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's 3-Year FCF Growth Rate falls into.



Epigenomics AG 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Epigenomics AG  (STU:ECX) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Epigenomics AG 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (STU:ECX) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.